"All Our Wisdom is Stored in the Trees" - Degrading BCR-ABL with Berberis Vulgaris

Clin Cancer Res. 2020 Aug 1;26(15):3899-3900. doi: 10.1158/1078-0432.CCR-20-0829. Epub 2020 May 12.

Abstract

Treating BCR-ABL-positive chronic myeloid leukemia remains impeded by the development of clinical resistance to imatinib. It has been demonstrated that berberine, a plant alkaloid, has activity against imatinib-resistant BCR-ABL mutants by inducing autophagic degradation of BCR-ABL, thereby preventing the acquisition of drug-resistant mutations.See related article by Yin et al., p. 4040.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Comment

MeSH terms

  • Antineoplastic Agents* / pharmacology
  • Benzamides / therapeutic use
  • Berberine* / therapeutic use
  • Berberis* / drug effects
  • Drug Resistance, Neoplasm / drug effects
  • Drug Resistance, Neoplasm / genetics
  • Fusion Proteins, bcr-abl / genetics
  • Humans
  • Imatinib Mesylate / therapeutic use
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / drug therapy
  • Leukemia, Myelogenous, Chronic, BCR-ABL Positive* / genetics
  • Piperazines / therapeutic use
  • Pyrimidines / therapeutic use
  • Trees / drug effects
  • Ubiquitin-Protein Ligases / therapeutic use

Substances

  • Antineoplastic Agents
  • Benzamides
  • Piperazines
  • Pyrimidines
  • Berberine
  • Imatinib Mesylate
  • LRSAM1 protein, human
  • Ubiquitin-Protein Ligases
  • Fusion Proteins, bcr-abl